MTOR inhibitor-associated dermatologic and mucosal problems

Clinical Transplantation

Volumn 24, Issue 2, 2010, Pages 149-156

  Campistol, Josep M ^a   de Fijter, Johan W ^b   Flechner, Stuart M ^c   Langone, Anthony ^d   Morelon, Emmanuel ^e   Stockfleth, Eggert ^f  

^a HOSPITAL CLÍNIC   (Spain)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Dermatologic complications; Immunosuppression; Renal transplantation; Sirolimus

Indexed keywords

ANTIHISTAMINIC AGENT; BENZOYL PEROXIDE; CALCINEURIN INHIBITOR; CETIRIZINE; CLOBETASOL; COTRIMOXAZOLE; EMOLLIENT AGENT; ERYTHROMYCIN; HYDROXYZINE; LORATADINE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METRONIDAZOLE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RETINOID; STEROID; TACROLIMUS; TEMSIROLIMUS; TETRACYCLINE; VALGANCICLOVIR;

ACNE; ACNE VULGARIS; ANGIONEUROTIC EDEMA; APHTHOUS ULCER; ARTICLE; CLINICAL TRIAL; DERMATITIS; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; EDEMA; EXFOLIATIVE DERMATITIS; FOLLICULITIS; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; HYPERSENSITIVITY REACTION; IMMUNE DEFICIENCY; INFECTION; INFLAMMATION; KIDNEY GRAFT REJECTION; LEUKOCYTOCLASTIC VASCULITIS; LIVER GRAFT REJECTION; LOADING DRUG DOSE; MOUTH ULCER; MUCOSAL DISEASE; NAIL DISEASE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RASH; RISK FACTOR; SKIN DISEASE; SKIN PRURITUS; STOMATITIS; THRUSH; VASCULITIS;

ACNE VULGARIS; ALGORITHMS; CALCINEURIN; EXANTHEMA; FOLLICULITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY TRANSPLANTATION; NAIL DISEASES; PROTEIN-SERINE-THREONINE KINASES; PRURITUS; SIROLIMUS; SKIN; STOMATITIS, APHTHOUS; VASCULITIS;

EID: 77952905485     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01232.x     Document Type: Article

References (34)

1. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000, 356:194.
2. Reitamo S, Spuls P, Sassolas B. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 2001, 145:438.
3. Mahé E, Morelon E, Lechaton S. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005, 79:476.
4. Mahé E, Morelon E, Lechaton S. Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects. J Am Acad Dermatol 2006, 55:139.
5. Schaffellner S, Jakoby E, Kniepeiss D. Center experience in liver transplantation (LTX): management of dermal side effects caused by sirolimus. Int Immunopharmacol 2005, 5:137.
6. Dereure O. Skin reactions related to treatment with anticytokines, membrane receptor inhibitors and monoclonal antibodies. Expert Opin Drug Saf 2003, 2:467.
7. Laffitte E, Saurat JH. Kinase inhibitor-induced pustules. Dermatology 2005, 211:305.
8. Nomura M, He Z, Koyama I, Ma WY, Miyamoto K, Dong Z. Involvement of the Akt/mTOR pathway on EGF-induced cell transformation. Mol Carcinog 2003, 38:25.
9. Ulrich C, Christophers E, Sterry W, Meyer T, Stockfleth E. Skin diseases in organ transplant patients. Hautarzt 2002, 53:524.
10. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004, 4:1869.
11. Peddi VR, Jensik S, Pescovitz M. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant 2005, 19:130.
12. Watson CJE, Firth J, Williams PF. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005, 5:2496.
13. Scully C. Clinical practice. Aphthous ulceration. N Engl J Med 2006, 355:165.
14. Shapiro AMJ, Lakey JRT, Ryan EA. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000, 343:230.
15. Mathew TH, Van Buren C, Kahan BD, Butt K, Hariharan S, Zimmerman JJ. A comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejection. J Clin Pharmacol 2006, 46:76.
16. Hardinger KL, Cornelius LA, Trulock EP, Brennan DC. Sirolimus-induced leukocytoclastic vasculitis. Transplantation 2002, 74:739.
17. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001, 71:271.
18. Toso C, Meeberg GA, Bigam DL. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007, 83:1162.
19. van Gelder T, ter Meulen CG, Hene R, Weimar W, Hoitsma A. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003, 75:788.
20. Schena FP, Pascoe MD, Alberu J. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009, 87:164.
21. Gonzalez-Moles MA, Morales P, Rodriguez-Archilla A, Isabel IRA, Gonzalez-Moles S. Treatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous solution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002, 93:264.
22. Chuang P, Langone AJ. Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus. Am J Transplant 2007, 7:714.
23. Pasqualotto AC, Bianco PD, Sukiennik TCT, Furian R, Garcia VD. Sirolimus-induced leukocytoclastic vasculitis: the second case reported [letter]. Am J Transplant 2004, 4:1549.
24. Nagarajan S, Friedrich T, Garcia M, Kambham N, Sarwal MM. Gastrointestinal leukocytoclastic vasculitis: an adverse effect of sirolimus. Pediatr Transplant 2005, 9:97.
25. Hugl B, Lhotta K, Ensinger C. Colonic perforation associated with leukocytoclastic vasculitis caused by sirolimus toxicity following renal transplantation [letter]. Transpl Int 2006, 19:430.
26. Sais G, Vidaller A, Jucglà A, Servitje O, Condom E, Peyrí J. Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients. Arch Dermatol 1998, 134:309.
27. Yee KWL, Hymes SR, Heller L, Prieto VG, Welch MA, Giles FJ. Cutaneous leukocytoclastic vasculitis in a patient with myelodysplastic syndrome after therapy with the rapamycin analogue everolimus: case report and review of the literature. Leuk Lymphoma 2006, 47:926.
28. Crowson AN, Mihm MCJ, Magro CM. Cutaneous vasculitis: a review. J Cutan Pathol 2003, 30:161.
29. Arvan ME, Brodell RT. A palpable clue to vasculitis. Postgrad Med 1999, 105:229.
30. ten Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother 2002, 36:130.
31. Mahé E, Morelon E, Lechaton S, Kreis H, de Prost Y, Bodemer C. [Sirolimus-induced onychopathy in renal transplant recipients]. Ann Dermatol Venereol 2006, 133:531.
32. Raju DL, Bitzan M. Sirolimus-associated chronic pyogenic periungual infection. Kidney Int 2007, 71:476.
33. Boni JP, Leister C, Bender G. Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 2005, 77:76.
34. Saray Y, Seçkin D, Güleç AT, Akgün S, Haberal M. Nail disorders in hemodialysis patients and renal transplant recipients: a case-control study. J Am Acad Dermatol 2004, 50:197.